Next Gen Sequencing

Reasons for SARS-CoV-2 optimism and a COVID-19 infographic

There is some reason in the US for optimism in the middle of this SARS-CoV-2 pandemic. I wrote earlier this week the absolute need for an antibody-based test for widespread public screening, to assess antibody responses to get a picture of who has been exposed to the virus and has generated an immune response against it. In addition to exposure, another urgent question is how many of the population are asymptomatic, and with the orthogonal technology of rRT-PCR to molecularly test for active virus infection, much can be learned about the natural course of COVID-19 disease and the spread of SARS-CoV-2 worldwide.

Dr. Birx said yesterday (here’s the YouTube link at the beginning of her remarks at a little over an hour in) talking about high-risk and low-risk counties, and importantly about the status of an antibody-based test. She talks about contact tracing expertise from the CDC, and discusses the need for POCT (point-of-care testing) beyond existing ELISA technology.

One interesting point was that SARS (“Classic”) antibodies cross-react ‘well’ to SARS-CoV-2. Another point she brings up is that contact tracing is ongoing now, just not well-publicized. She pointed out that the capability exists to have a ‘laser-focused’ approach (down to GPS coordinates) to get information on the spread in near real-time.

Vice President Pence indicated ’15 days to slow the spread’ campaign was to buy time for this kind of activity in the background. Also he pointed out (around 40′ into the press conference) that Abbott Laboratories ‘submitted today to the FDA’ an application for an antibody POCT for SARS-CoV-2 immunity / evidence of exposure. It is very likely on the iStat platform, as it currently is FDA approved for several blood metabolites using ELISA chemistry in a handheld device.

If we are on the verge of widespread contact tracing next week, I thought it appropriate to adapt this infographic from a German newsweekly called Die Ziet that I was able to obtain a good translation. (If you can read German the original graphic is found here.)

Here’s a link to the infographic as a PDF, and the image is below.

Dale Yuzuki

A sales and marketing professional in the life sciences research-tools area, Dale currently is employed by Olink as their Americas Field Marketing Director. https://olink.com For additional biographical information, please see my LinkedIn profile here: http://www.linkedin.com/in/daleyuzuki and also find me on Twitter @DaleYuzuki.

Share
Published by
Dale Yuzuki

Recent Posts

Observations about Helicos, a single molecule sequencer from 2008

Take a look at the latest blog post from Dale Yuzuki, published on the Silent…

2 years ago

Silent Valley Consulting – open for business

Silent Valley Consulting logo Life sciences marketing consulting for technical writing, content marketing, strategy and…

2 years ago

Proteomics in Proximity: Co-Hosting a New Podcast

Do you listen to podcasts? Would you be interested in learning about how Olink Proteomics'…

3 years ago

Discovery of a novel mechanism unique to severe COVID leads to a potential treatment

In a large meta-analysis, circulating protein levels of severe COVID patients along with many thousands…

3 years ago

A 2022 NGS Cost and Throughput Comparison

With Singular Genomics announcing the new G4 system at the end of 2021, and Element…

3 years ago

Element Biosciences AVITI™ Sequencing System

A new approach to next-generation sequencing, a little-known company unwraps an instrument that competes directly…

3 years ago